Ophthalmic Drugs: World Market Prospects 2012-2022


March 16, 2012
183 Pages - SKU: VSG3871639
License type:
Table of Contents Related Reports
Countries covered: Global

Ophthalmic Drugs: World Market Prospects 2012-2022

  enlarge


How to find trends and revenue predictions for the ophthalmic drug industry

What are the commercial prospects for treating eye disorders? Visiongain's report shows you potential revenues to 2022 - data, forecasts and discussions.

This study investigates prescription drugs treating human eye diseases. It lets you assess forecasted sales trends at world market, therapeutic submarket, product and national level to 2022.

How will 20 leading ophthalmic drugs - including Lucentis, Visudyne, Xalatan/Xalacom and Restasis - perform from 2012? Our investigation gives you business research and analysis with sales forecasts.

You also see forecasting of five submarkets to 2022, finding potential revenues:
  • Glaucoma treatments
  • Anti-allergy, anti-inflammatory and anti-infective agents
  • Retinal disorder treatments
  • Dry eye treatments
  • Other medicines.
Find coverage of the R&D pipeline too, by therapeutic area, assessing trends and outlooks.

What will happen next? The pharma industry will improve treatment of ocular disorders and increase revenues there. The R&D pipeline in ophthalmology is strong. Also, improved drug delivery and new formulations will be important.

Visiongain predicts that the world market for ocular drugs will grow strongly from 2012 to 2022. It will be stimulated by increasing prevalence of eye disorders among aging populations. Some national treatment markets will grow fast; others will expand slowly.

What are leading companies doing? Our work discusses Allergan, Novartis, Pfizer, Roche and other pharmaceutical companies, evaluating prospects of the industry and market.

Sustained-release ocular implants, gene therapy and RNA interference technology will influence R&D, as will neuroprotective agents for glaucoma. Pipeline developments have strong potential. In 2012, under-met treatment needs remain.

What effects will competition have? New products - novel small molecules, generics and biologics - will change the sector. Many commercial opportunities for ophthalmic drugs exist, with high revenues possible to 2022. Our report shows and explains.

Revenue forecasts, market shares, developmental trends and discussions

In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 120 tables and charts and six research interviews.

Eight ways Ophthalmic Drugs: World Market Prospects 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:
  • Find potential revenues to 2022 for the world market and submarkets
  • Discover revenue forecasts to 2022 for 20 leading products
  • See market forecasting to 2022 for US, Japan, EU5, Brazil, China and India
  • Assess leading companies, discovering activities and outlooks
  • Review R&D, seeing pipeline trends by therapeutic area
  • Investigate competition and opportunities influencing sales
  • Find out what will stimulate and restrain the industry and market
  • View opinions from our survey, interviews with external authorities.
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. This password will be set up for single user and departmental licenses and will be emailed out to the client at the same time as the report. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


Additional Information


Report Excerpt

6.2.3 Lucentis Sales Forecast, 2012-2022

Lucentis dominated the market in 2010 and 2011, owing to its reportedly superior efficacy over competitor treatments. Total revenues were $2935m in 2010 and $3707m in 2011 compared with $2338m in 2009. Nevertheless, visiongain predicts that there is scope for further growth, and that revenues will increase from 2012 to 2016. The major drivers for this growth will be the rapidly- increasing prevalence of AMD worldwide, combined with the likely expansion of approved indications to include treatment of DR.

Companies Listed

Acucela
Alcon (Novartis)
Alimera Sciences
Allergan
American Academy of Ophthalmology (AAO) [US]
American Society of Retina Specialists (ASRS) [US]
Apotex
Asahi Glass
Association for Research in Vision and Ophthalmology
AstraZeneca
Bausch & Lomb
Bayer
Biovitrum
Bristol-Myers Squibb
Can-Fite BioPharma
Cerimon Pharmaceuticals
Chugai Pharmaceutical Corp.
CombinatoRx
CoMentis
Daiichi Sankyo
Danube Pharmaceuticals
Eli Lilly
Esteve
European Medicines Agency (EMEA/EMA)
EyeGate Pharmaceuticals
Eyetech Pharmaceuticals
Food and Drug Administration (FDA) [US]
Fovea Pharmaceuticals
Galderma International SA (Nestlé and L'Oréal)
Genentech
GlaxoSmithKline
Gruenenthal
InSite Vision
Inspire Pharmaceuticals
ISTA Pharmaceuticals
Johnson & Johnson
Kowa Company
Kyorin Pharmaceutical Co.
Kyowa Hakko Kirin Corp.
Laboratorios Sophia
LEO Pharma
Lux Biosciences
Meda Pharmaceuticals
Merck & Co.
Ministry of Health, Labour and Welfare [Japan]
Moorfields Eye Hospital [UK]
Mylan
National Eye Institute (NEI) [US]
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
Neurotech
NicOx
NovaBay Pharmaceuticals
Novartis
Novex
Ophthotech
OPKO Health
OSI Pharmaceuticals
Othera Pharmaceuticals
Otsuka Pharmaceutical Corp.
Oxford Eye Hospital [UK]
OXiGENE
Paladin Labs
Pfizer
pSivida
QLT
Quark Pharmaceuticals
Ranbaxy Laboratories
Regeneron Pharmaceuticals
ReVision Therapeutics
Roche
Rutgers University, Springfield, New Jersey [US]
Santen Pharmaceutical Corp.
Sanwa Kagaku Kenkyusho Corp.
SARcode Corporation
Senju Pharmaceuticals
Shire Pharmaceuticals
Sirion Therapeutics
Sirna Therapeutics
SKS Ocular
Sunesis Pharmaceuticals
Symphony ViDA
Takeda Pharmaceuticals
Targeted Genetics
Teva Pharmaceutical Industries
ThromboGenics
University College of London (UCL), Institute of Ophthalmology [UK]
University of Aston, Birmingham [UK]
University of Oxford [UK]
Watson Pharmaceuticals

More Ophthalmology reports by Visiongain

Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021 by Visiongain
What are the commercial prospects for the treatment of macular degeneration (AMD) and diabetic retinopathy (DR)? Our new report shows you potential revenues to 2021, ...
Ophthalmic Drugs: World Market 2011-2021 by Visiongain
Where will the highest revenue growth occur in the ophthalmic drug market? Our new report shows you the eye disorder treatment market's potential from 2011 ...
See all reports like this >>

More Global Ophthalmology reports

Global Eye Care Surgical Market  2012-2016 by Infiniti Research Limited
Global Eye Care Surgical Market  2012-2016TechNavio's analysts forecast the Global Eye Care Surgical market to grow at a CAGR of 8.54 percent over the period ...
Biomaterials Market [By Products (Polymers, Metals, Ceramics, Natural Biomaterials) & Applications (Cardiovascular, Orthopedic, Dental, Plastic Surgery, Wound Healing, Tissue Engineering, Ophthalmology, Neurology Disorders)] – Global Forecasts to 2017 by MarketsandMarkets
A biomaterial is a natural or synthetic material suited to replace or treat natural body tissues and organs on interaction with biological systems. It traces ...
Open-Angle Glaucoma Global Clinical Trials Review, H1, 2013 by GlobalData
Open-Angle Glaucoma Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, “Open-Angle Glaucoma Global Clinical Trials Review, H1, 2013 provides data on the Open-Angle Glaucoma ...
Intraocular Lens (IOL): Market Shares, Strategies, and Forecasts, Worldwide, Nanotechnology, 2013 to 2018 by WinterGreen Research
WinterGreen Research announces that it has published a new study Intraocular Lens (IOL) Market Shares, Strategy, and Forecasts, Worldwide, 2013 to 2018. The 2013 study ...
See all reports like this >>

 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Ophthalmology Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!